October 22, 2015 -- Chanting “Hey-Hey, ho-ho, pharma greed has got to go!” a group of protesters from the AIDS Healthcare Foundation protested in front of the headquarters building of PhRMA in Washington, DC today. … [Read more...]
HRSA Proposes Changes to 340B Pharmaceutical Pricing Agreement
Collecting public comments until December 21, 2015October 21, 2015 - The Health Resources and Services Administration is seeking public comments about proposed changes to the current Pharmaceutical Pricing Agreement (PPA). … [Read more...]
Court Rules in PhRMA’s Favor on Orphan Drugs
Rejects government argument on using 340B pricing for common disease indicationsA federal court today soundly rejected the Department of Health and Human Service’s interpretation of the 340B statute’s orphan drug exclusion as it relates to providers added to the program in the Affordable Care Act in 2010. The ruling means that rural and cancer hospitals will no longer be able to get 340B pricing on any orphan drug. … [Read more...]
Second Generic Drugmaker in a Month Acknowledges 340B Overcharges
Zydus, like Heritage before it, is under investigation for price increasesOctober 6, 2015—For the second time in less than a month, a generic-drug manufacturer under congressional investigation for price increases has announced that it owes 340B covered entities refunds due to overcharges. … [Read more...]
340B Comes Up During Two Congressional Hearings
Questions asked about program's possible effects on Medicare and private cancer clinicsOctober 1, 2015—Questions about whether hospitals' 340B drug discounts might be costing Medicare more and harming private cancer clinics were asked at two hearings on Capitol Hill this morning. … [Read more...]
Drug Industry Complimentary of Proposed Rules
AIR 340B urges HRSA to be more assertive toward providersSeptember 30, 2015—The Health Resources and Services Administration’s proposed 340B mega-guidance is an "encouraging first step" toward reform, says the drug-industry-led group AIR 340B in a new communiqué. … [Read more...]
Congress Wants Drug Makers to Explain Price Increases
Lawmakers call Valeant CEO to appear alongside Turing CEO at hearingSeptember 29, 2015—Eighteen members of the House Oversight and Government Reform Committee have asked Chairman Jason Chaffetz (R-Utah) to “issue a subpoena compelling Valeant Pharmaceuticals to turn over documents the company is withholding from Congress relating to massive price increases earlier this year for two drugs used by hospitals and other providers to treat serious … [Read more...]